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The serine/threonine phosphatase PP5 regulates hormone and
stress-induced cellular signaling by association with the molec-
ular chaperone Hsp90. PP5-mediated dephosphorylation of the
cochaperone Cdc37 is essential for activation of Hsp90-dependent
kinases. However, the details of this mechanism remain unknown.
We determined the crystal structure of a Cdc37 phospho-mimetic
peptide bound to the catalytic domain of PP5. The structure reveals
PP5 utilization of conserved elements of phosphoprotein phos-
phatase (PPP) structure to bind substrate and provides a template
for many PPP-substrate interactions. Our data demonstrates that
despite a highly conserved structure, elements of substrate speci-
ﬁcity are determined within the phosphatase catalytic domain
itself. Structure-based mutations in vivo reveal that PP5-mediated
dephosphorylation is required for kinase and steroid hormone
receptor release from the chaperone complex. Finally, our data
shows that hyper- or hypoactivity of PP5 mutants increases Hsp90
binding to its inhibitor. This provides a mechanism to enhance the
efﬁcacy of Hsp90 inhibitors by regulation of PP5 activity in tumors.
Hsp90 j PP5 j Cdc37 j chaperone j phosphatase
Protein phosphatase 5 (PP5/Ppp5) has pleiotropic roles in
cellular signaling including DNA damage repair, proliferation
of breast cancer cells, circadian cycling, response to cytotoxic
stresses, Rac-dependent potassium ion channel activity and acti-
vation of steroid hormone receptors (e.g. glucocorticoid receptor
(GR) and estrogen receptor (ER)) (1, 2). It is a member of the
phosphoprotein phosphatase (PPP) family of serine/threonine
phosphatases, whose members share a highly conserved catalytic
core and catalytic mechanism, dependent on two metal ions,
commonly Mn2+. Most PPP family members exhibit high, non-
specific phosphatase activity. Specificity is provided by a large co-
hort of regulatory and other interacting proteins that function to
inhibit basal activity and recruit substrates, thereby finely tuning
the enzymes (3). This combinatorial approach enables a small
number of catalytic subunits to have the breadth of specificity
equivalent to that seen in kinases, which are greater in number
by an order of magnitude. Structures of complexes between reg-
ulatory and catalytic domains have illuminated the importance
of regulatory subunits in facilitating substrate recruitment (3).
However, to date there is no structural information describing
how a substrate binds at the active site of a PPP, therefore
a central question remains how local interactions between the
substrate and the catalytic domain contribute to the molecular
basis of dephosphorylation.
PP5 is unique amongst the PPP family as it has a low basal
activity due to an autoinhibitory N-terminal TPR domain (4). Its
activity is promoted by a number of cellular factors, including
fatty acids and the molecular chaperone Hsp90 (5), both of which
release autoinhibition by interacting with the TPR domain (6,
7). Many established PP5 substrates are dependent on Hsp90
for their activation (known as Hsp90 clients). In addition to a
requirement for Hsp90’s chaperone activity, it is likely that these
PP5 substrates require Hsp90 to act as a molecular bridge to
bring the catalytic domain of PP5 in close proximity enabling
dephosphorylation, as has been demonstrated for the Hsp90
cochaperone, Cdc37 (8). In such cases Hsp90 performs a role
similar to that observed by the regulatory subunits of the PP1 and
PP2A family (3).
The cochaperone Cdc37 regulates the activation of Hsp90
client-kinases by distinguishing between client and non-client
kinases (9) and recruiting them to Hsp90 (10). Many of these
kinases are oncogenes therefore the molecular details of their ac-
tivation are of considerable interest in cancer therapy. Activation
is dependent on a cycle of Cdc37-Ser13 phosphorylation by the
constitutively active kinase CK2 (11, 12), and dephosphorylation
by PP5 (8). The mechanisms by which Cdc37 phosphorylation
and dephosphorylation, and any accompanying conformational
changes, regulate kinase activation is not understood.
In order to understand the molecular determinants of the
phospho-Ser13 Cdc37-PP5 interaction, we determined the 2.3
Å crystal structure of a Cdc37 phospho-mimetic peptide, bound
to the catalytic domain of PP5. The structure reveals how PP5
utilizes conserved elements of PPP structure to bind substrate
while in vitro and in vivo analysis indicate that, despite being highly
Signiﬁcance
The activity of many proteins is dependent on molecular
chaperones and their accessory proteins, cochaperones. The
ability of a cohort of kinases, many of which are oncogenic,
to transduce signals is promoted by the Hsp90 chaperone and
Cdc37 cochaperone. This requires the removal of a phosphate
from Cdc37 by the phosphatase PP5. We present the crystal
structure of the PP5 phosphatase with Cdc37 trapped in the
active site. This reveals how PP5 can associate with different
substrates and previously unknown determinants of speci-
ﬁcity. Our ﬁndings show kinase release from the chaperone
complex is critically dependent on this dephosphorylation and
that combined inhibition of both Hsp90 and PP5 could provide
an effective therapeutic strategy for treating cancers addicted
to these kinases.











































































































































Fig. 1. Structure of Cdc37 phosphomimetic substrate bound in the PP5
catalytic cleft (A) Stereo image of the 2mFo-DFc electron density map con-
toured at 1σ for the Cdc37 phosphomimetic peptide. The peptide is coloured
from blue (Trp7) to red (Asp15). Water molecules (red spheres) and Mn2+
ions (purple spheres) are shown. (B) The Cdc37-bound PP5 catalytic domain.
Cdc37 is shown as sticks (coloured as (A)); PP5 is in cartoon representation.
Cdc37-Trp7 and Asp8 do not make contact with the catalytic domain and
are omitted for clarity. Sheets, helices and loops are coloured yellow, blue
and grey respectively; the β12-13 loop is purple; the PP5 speciﬁc C-terminus
is orange. The location of the αJ-helix from the apo PP5 catalytic domain
structure (1S95) is shown in transparent magenta, generated by an rms ﬁt of
1S95 and the chimera structure. The rest of 1S95 is omitted for clarity (see Fig.
S1D for the complete ﬁt).(C) Interactions between residues of the catalytic
site of PP5 (grey) and the phosphomimetic Glu13 of Cdc37 (orange) including
watermolecules (red) andMn2+ ions (purple). The newwatermolecule found
in the phosphomimetic structure is coloured magenta. Differences in the
PO43- bound apo structure (PDB 1S95) are shown in transparent pink. (D)
Hydrogen bonds (black dashed lines) between the Cdc37 peptide and PP5
(coloured as (B)). The catalytic residues interacting with E13 are omitted for
clarity. Those involving the catalytic residues R275 and R400 are shown in
pink.
conserved, elements of substrate specificity are determinedwithin
the phosphatase catalytic domain itself.
Results
Crystal Structure of the PP5-Cdc37 Complex
Cocrystallisation of the PP5 catalytic domain with Cdc37
peptides in which the phospho-mimetic mutation Ser13→Glu was
introduced to trap the substrate in the phosphatase active site,
yielded crystals with either no, or very low, peptide occupancy.
In vivo and in vitro PP5-mediated dephosphorylation of phospho-
Cdc37-Ser13 requires Hsp90 to act as both a PP5-activator and a
PP5-substrate recruiter. In order to obtain a construct suitable for
crystallisation, we circumvented the need for Hsp90 by utilizing a
chimera construct in which the TPR domain of PP5 was deleted
and a peptide comprising residues 5-20 of Cdc37, including the
Ser13→Glu mutation, was covalently linked to the catalytic do-
main of PP5 via a flexible linker of 9 residues (Fig. S1a). This
construct yielded crystals that diffracted to 2.3 Å (Table S1).
In the resulting structure there is clear electron density for
the Cdc37 peptide from Trp7 to Asp15 (Figure 1a), bound in an
extended conformation across the dimetallic active site of PP5
(Figure 1b). The entire catalytic domain of PP5 is also clearly
defined in the electron density with the exception of residues
491-499 (see below) and several side-chains on the surface of the
protein remote from the catalytic centre. The overall orientation
of the substrate peptide is identical to that of the microcystin
Fig. 2. Substrate main-chain conformation is likely to be conserved
throughout PP5 and PPP family members (A, B) Surface representation of PP5
and (C, D) Cdc37 substrate-binding residues coloured according to sequence
conservation using Consurf (see Methods). (A) and (C) show conservation
between PP5 homologues; (B) and (D) show conservation amongst PPP family
phosphatases. Cdc37 substrate is shown as sticks, coloured as Figure 1A and
labeled from -4 through +2 to identify location relative to phosphomimetic
S13E (position 0).
(13), okadaic acid (14), nodularin and tautomycin (15) classes of
PPP toxin inhibitors (Fig. S1b). Three putative substrate-binding
clefts radiate from the catalytic centre of the PPP family member,
PP1 (16). In PP5, two of these are occupied by Cdc37. Substrate
residues N-terminal of S13E lie in the ‘hydrophobic groove’ while
the C-terminal end of the substrate occupies the ‘C-terminal
groove’ (Fig. S1c).
There are no significant global structural changes in the PP5
catalytic domain on binding the Cdc37 substrate peptide. The
RMSD between the Cdc37-bound and PO43--bound (PDB 1S95)
(17) structures is 0.391 Å (Fig. S1d). With the exception of the
N- and C-termini of the domain and regions involved in crystal
packing, the principal differences in main-chain and side-chain
orientation lie around the substrate-binding cleft. This includes
Asn308, Ile312, Pro376, Gly401 and Val402, all of which provide
either van der Waals or hydrogen bond contacts with the peptide.
The largest difference between the apo and holo crystal structures
is the absence of density for the αJ-helix of the PP5-specific C-
terminal subdomain. This may be a result of the design of the
chimera as both the αJ-helix and the substrate are parallel to each
other (Figure 1B). Nonetheless the location of this subdomain in
the PO43--bound enzyme is not compatible with the direction of
the substrate peptide C-terminal to Asp15. This suggests the αJ-
helix plays a role in regulation of PP5 activity, not only through
stabilizing the auto-inhibitory state of the TPR domain (6), but
also by steric exclusion of the substrate.
The phospho-mimetic residue S13E is bound deep in the
active site of the PP5 catalytic domain and the carboxylate group
occupies the same location as the bound phosphate in the holo
structure (Figure 1c). A new water molecule fills the cavity left
by one of the missing oxygen atoms of the phosphate. The con-
formation of almost all residues involved in coordinating Cdc37-
S13E, and the active site waters and Mn2+ ions, is unchanged
compared to the phosphate-bound holo structure (17). The ex-
ception is Arg275 for which the guanadinium group has flipped.










































































































































Submission PDFFig. 3. Structure-based mutations reveal the functional importance ofspeciﬁc interactions between PP5 and substrate in vitro and in vivo (A)Dephosphorylation of phospho-Cdc37-Ser13 in the context of puriﬁed, full-
lengthWT and indicatedmutants of Cdc37 and PP5, in the presence of Hsp90.
Activity was assessed using a phospho-speciﬁc antibody over time (minutes).
(B) HEK293 cells were transiently transfected with empty plasmid (C), WT
Cdc37-FLAG, or indicated mutants. Cdc37-FLAG proteins were immunopre-
cipitated (IP). Co-IP of Hsp90 and PP5 were examined by immunoblotting, (C)
HEK293 cells were transiently transfected with empty plasmid (C), WT Cdc37-
FLAG or indicated mutants. Cdc37-FLAG proteins were immunoprecipitated
(IP) and the level of phospho-Ser13 examined by immunoblotting. Co-IP of
CK2 and Hsp90 client kinases CDK4, Raf-1, and ULK1 were also examined by
immunoblotting.(D) Total protein lysates were prepared from HEK293 cells
transiently transfected with empty plasmid (C), WT PP5-c-myc, or indicated
mutants. Cdc37, phospho-Ser13-Cdc37, GR and phospho GR-211 protein
levels were examined by immunoblotting.
trapped substrate, since all residues and active site waters are in
orientations that are suitable for the in-line nucleophilic attack
proposed for the catalytic mechanism (17).
The majority of H-bonds that determine the substrate con-
formation are from the substrate backbone amide groups, with
all residues except His9 and Glu11 making contributions (Fig-
ure 1d). In the phosphatase domain, these interactions are con-
tributed by PP5-Arg275, Asn308, Tyr313, Arg400 and Tyr451.
Of these residues, Arg275 and Arg400 are also involved in the
catalytic mechanism, and Tyr451 is part of the β12-13 loop, whose
conformation is sensitive to the binding of some toxin inhibitors
(16). The main-chain of the phosphomimetic Cdc37-S13E is co-
ordinated via both its amino and carbonyl groups to the hydroxyl
of PP5-Tyr313.
The peptide adopts an ‘in-out-in-out’ conformation, with the
side-chains of His9, Glu11 and Glu14 orienting towards, and
Ile10, Val12 andAsp15 orienting away from the surface of the PP5
catalytic domain. The side-chains of His9, Glu11 andAsp14make
direct or water-mediated H-bonds to PP5. Cdc37-His9 takes a
highly unusual rotamer conformation to make a direct H-bond
with the hydroxyl group of Tyr313. Cdc37-Glu11 is buried in a
deep groove and makes water-mediated hydrogen bonds with
the backbone carbonyl groups of PP5-Pro375 and Pro376. The
carboxylate group of Asp14 makes water-mediated interactions
with themain-chain of Val429 and the side-chain ofGlu428 within
the PP5 acidic groove. Significant van der Waals interactions are
contributed from PP5-Trp386, Met309, Ile312 and Asn308.
Conservation Analysis of the PP5–Cdc37 Interaction
Fig. 4. Inactive mutants of PP5 cause client proteins to be stalled in the
Hsp90 chaperone complex in vivo (A) Empty plasmid (C), WT PP5-c-myc, or
indicated mutants were transiently transfected in HEK293 cells. PP5 proteins
were immunoprecipitated (IP). Co-IP of Hsp90, CDK4, GR were examined
by immunoblotting. (B) Immunoprecipitation (IP) of empty plasmid (C),
PP5-FLAG WT, or mutants from transiently transfected HEK293 cells were
immunoblotted for co-IP of Raf-1. (C) Empty plasmid (C), PP5-FLAG WT or
mutants were transiently expressed in HEK293 cells. Lysates were incubated
with 50 or 100 nM biotinylated-ganetespib (GB). Using streptavidin beads,
Hsp90 and PP5 bound to the drug were isolated and immunoblotted. (D)
HEK293 were transiently transfected with control and PP5 siRNA. Lysates
were incubated with indicated amounts of biotinylated-ganetespib (GB).
Using streptavidin beads, Hsp90 bound to the drug was isolated and im-
munoblotted.
In addition to almost complete conservation of the catalytic
residues within the PPP family of serine/threonine phosphatases
(3), the substrate-binding cleft in PP5 is strongly conserved,
both amongst PP5 homologues (Figure 2a) and between PPP
family members (Figure 2b). A detailed analysis reveals that the
interactions that dictate Cdc37 backbone conformation involve
either PP5 main-chain groups, whose orientation is likely to be
invariant in PP5 homologues, or side-chains with greater than
98% sequence identity (out of 69 homologues analysed) (Figure
2c, Table S2, Fig. S2a). In addition, since sequence and structural
conservation of PPP catalytic domains is extremely high (Fig.
S2b, S2c), interactions involving backbone groups are likely to be
conserved not only amongst PP5 homologues, but also between
PPP family members (Figure 2d). This striking conclusion also
holds for the side-chains that interact with the substrate main-
chain: these residues have greater than 79% sequence similarity
amongst 87 PPP family members analysed (Figure 2d, Table S2,
Fig. S2c). The only exception to this strong conservation is PP5-
N308: while there is a predominant ability of the residue at this
position to form hydrogen-bonds (94% of PP5 homologues, 99%
of PPP family members) Asn308 is not highly conserved, either
within the PPP superfamily or even the PP5 family (Fig. S2a,
S2b). Therefore there is a greater likelihood of differences in
the backbone conformation of the substrate in the -3 position.
We conclude from this analysis that it is possible that many PPP











































































































































will adopt the main-chain conformation seen for Cdc37, at least
from the -2 to +2 position.
The Cdc37 side-chains Glu11 and Asp14 at the -2 and +1
positions respectively both contribute water-mediated hydrogen
bonds with PP5, and sit in grooves that are conserved and spa-
cious relative to the size of the side-chain itself. Analysis of
the hydrophobic nature of these grooves (Fig. S2d) and crystal
structures of the toxin inhibitors of the PPP family illustrate that
both polar and non-polar groups can be found in each of these
sites (13-15). Therefore it is likely that PP5, and indeed members
of the PPP superfamily in general, can accommodate substrates
with side-chains of different sizes and properties at the -2 and +1
positions, and that water molecules will play a role in moulding
the substrate to the enzyme.
Mutational Analysis of PP5-Substrate Interactions in Vitro
and in Vivo
In order to test our structure and conservation-based predic-
tions of the relative importance of residues in both the enzyme
and the substrate for determining specificity, we introduced a
series of mutations in full-length PP5 and Cdc37 and assessed
their activity in a dephosphorylation reaction in the presence or
absence of Hsp90 (Figure 3a, Fig. S3a). PP5 residues previously
identified as involved in coordination of phosphate or Mn2+ ions,
or proposed to have a role in the mechanism of dephosphoryla-
tion, were not modified. To confirm that the chosenmutations did
not disrupt the catalytic mechanism of PP5, all PP5 mutants were
initially tested for their ability to dephosphorylate pNPP, a com-
monly used small molecule for assaying non-specific phosphatase
activity (Fig. S3b). With the exception of W386F (hyperactive)
and Y313F (approximately half as active as the wild-type (WT)),
all other mutants displayed similar kinetics of dephosphorylation
to the WT, indicating that the mutations did not cause significant
structural disruption to the active site.
Mutations of PP5 residues that are involved in direct coordi-
nation (N308D, Y313F) or providing van der Waals interactions
(M309C) to the Cdc37 substrate main-chain result in loss of
activity, indicated by phospho-Cdc37-Ser13 detection using pu-
rified proteins in vitro, whereas the conservative mutation N308Q
has no effect on Cdc37-Ser13 dephosphorylation (Figure 3a).
For the substrate, all of the changes to residues that interact,
either directly or through water-mediated interactions with PP5
(H9A, E11A/Q, and D14N) results in loss of dephosphorylation.
By contrast mutation of the conserved residue Ile10 to alanine,
whose side-chain is oriented away from the surface of PP5, has
no effect on dephosphorylation. A careful balance of polar and
charged groups is essential in directing the PP5-Cdc37 interaction
since the mutations PP5-N308Q and Cdc37-E11D have minimal
effect on dephosphorylation, whereas altering the electrostatic
environment with the mutations PP5-N308D or Cdc37-E11Q,
cause loss of activity.
To investigate the consequences of these mutations for the
substrate - phosphatase interaction in vivo, FLAG-Cdc37 wild-
type and mutants (H9A, E11A, D14N) (Figure 3b,3c) were tran-
siently expressed and immunoprecipitated from HEK293 cells.
Cdc37mutants that were not dephosphorylated in vitro (H9A,
E11A, D14N), lose their interaction with PP5 in vivo while retain-
ing wild type-like interaction with Hsp90 (Figure 3b). Reciprocal
co-immunoprecipitation experiments show that this is a conse-
quence of the direct interaction between PP5 and Cdc37, as the
Cdc37 mutations do not alter the interaction between PP5 and
Hsp90 (Fig. S3c).
However, loss of interaction with PP5 does not result in
an increase of phospho-Cdc37-Ser13. Instead phosphorylation
of Cdc37 is diminished (Figure 3c). A positive feedback loop
between CK2 and Cdc37 regulates the activation of the former,
and the phosphorylation of the latter (18, 19). His9, Glu11 and
Asp14 form part of the highly conserved N-terminal region of
Cdc37 (Fig. S3d) that is required for client-kinase binding to
Cdc37 (9, 20-23). These mutations disrupt this feedback mech-
anism, diminishing or preventing phosphorylation of Cdc37 by
CK2 because they prevent recruitment of CK2 to Cdc37 (Figure
3c), despite not overlapping with the CK2 consensus sequence
(SXXE/D) (Fig. S3d) or residues implicated in direct association
with the client kinase B-Raf (9). Consequently recruitment of
ULK1, Raf-1 and Cdk4, known Hsp90 client-kinases, is also
affected, as this in turn is dependent on Cdc37 phosphorylation
(Figure 3c). These results emphasize the essential nature of the
polypeptide sequence surrounding Cdc37-Ser13 in client-kinase
activation, and expand the known residues in this N-terminal
region that are essential for productive client-kinase chaperoning
(9, 20).
Mutations in the catalytic cleft of myc-tagged PP5 (N308D,
M309C, Y313F, W386F) strongly diminish dephosphorylation of
phospho-Cdc37-Ser13 in cells, when compared to myc-tagged
WT PP5 (Figure 3d), as seen in vitro, as well as impairing PP5’s
ability to dephosphorylate phospho-GR-Ser211, another known
target of PP5 discussed in detail later (2). This data is in agree-
ment with our previous work in which overexpression of PP5 in
HCT116 colon cancer cells enhanced Cdc37 dephosphorylation
(8).
Implications for Hsp90-Dependent Activation of Client Pro-
teins
PP5-mediated dephosphorylation of Cdc37 is an essential
step in the activation of Hsp90-dependent kinases. Dysregulation
of this step, by overexpression of PP5 with concomitant reduction
in phospho-Cdc37-Ser13, results in reduced Raf-1 activity in
HCT116 cells and in yeast both the overexpression and deletion
of the orthologue, Ppt1, causes reduced v-Src activity (8). In
order to understand how Cdc37 dephosphorylation affects the
activation mechanism of Hsp90-dependent kinases we investi-
gated the impact of PP5 mutants on chaperoning of the kinase
clients Cdk4 and Raf-1. The PP5 mutants were immunoprecip-
itated and their interaction with Cdk4 and Hsp90 was assessed
by immunoblotting. Cdk4 did not co-immunoprecipitate withWT
PP5, presumably due to its dynamic interaction within the Hsp90
chaperone cycle. However, the N308D, M309C and Y313F PP5
mutations, that prevent the dephosphorylation of Cdc37 in vitro
and in vivo, trap the kinase in theHsp90-PP5 complex (Figure 4a).
We also observed similar results with PP5 mutants’ interaction
with Raf-1 (Figure 4b). Co-immunoprecipitation of Hsp90 with
PP5 mutants at steady state shows that they bind to Hsp90 with
similar affinity, with the exception of theW386F mutant, which is
hyperactive, resulting in a transient interaction (Figure 4a). These
results provide mechanistic details that elaborate our previous
work (8) demonstrating that kinase release from the chaperone
complex is critically dependent on Cdc37 dephosphorylation by
PP5.
Hyperactivity or hypoactivity of PP5 mutants enhances
Hsp90 binding to drug
It is well established that increased binding of Hsp90 to its
inhibitors is associated with sensitivity of cells to Hsp90 drugs
(24, 25). We have previously shown that overexpression of the
yeast PP5 ortholog (Ppt1) sensitizes cells to the Hsp90 inhibitor
geldanamycin (8). We reasoned that PP5 mutants might influ-
ence Hsp90 inhibitor association therefore, we expressed FLAG-
PP5 WT and mutants in HEK293 cells followed by biotinylated-
ganetespib (biotinylated-GB) pulldown experiments. Our data
showed that the hypoactive (N308D, M309C and Y313F) and
hyperactive (W386F) PP5 mutants significantly enhanced Hsp90
binding to biotinylated-GB (Figure 4c). Although PP5 mutants
bound with similar affinity as theWTPP5 toHsp90 at steady state
(Figure 4a), these mutants differentially impacted Hsp90 binding
to its inhibitor ganetespib. Additionally, once Hsp90 was bound











































































































































mutants (Figure 4c).We obtained further evidence to support our
hypothesis by down regulating PP5 using siRNA (Figure 4d, Fig.
S4). These data suggest that the activity of PP5 is a determining
factor for Hsp90 affinity to its inhibitor.
Implications for PP5 Specificity
Having established that particular residues in the catalytic
cleft are necessary for Cdc37 recognition, the question arises
whether these residues are able to confer specificity of phos-
phatase activity, i.e. does their mutation have differential effects
on different substrates? PP5 also dephosphorylates GR, another
Hsp90 client, at Ser203, Ser211 and Ser226 and subsequently
controls its activity and nucleo-cytoplasmic translocation (2). To
examine specificity we therefore investigated the consequences
of mutations in the PP5 catalytic cleft on its ability to dephos-
phorylate GR-Ser211. Mutations of PP5-M309C and Y313F pre-
vent dephosphorylation of GR-Ser211, as observed with Cdc37
(Figure 3d). In addition, an equivalent trapping of GR on Hsp90-
containing PP5 complexes is observed for the M309C mutation
(Figure 4a). TheY313Fmutation does not result in a trappedGR-
complex, but as this mutant has an activity profile that is distinct
from the other mutants (Fig. S3b) this may be a result of unpre-
dicted structural changes in the vicinity of the substrate-binding
site. However, unlike the case for Cdc37, the PP5-N308D mutant
had no effect on dephosphorylation of GR-Ser211. In the PP5-
Cdc37 structure the side-chain of Asn308 provides interactions
with the backbone carbonyl of Cdc37-Ile10 and the carboxylate of
Glu11, as well as van derWaals contacts to Glu11. The equivalent
position for GR phospho-Ser211 substrate is Asn209 (sequence
TNEpSPWR), therefore the PP5-N308D mutant may provide
similar electrostatic interactions to WT PP5. In agreement with
our structural analysis, the contrasting effect of this mutation on
different substrates confirms that the binding groove on PP5 for
the substrate -2 position provides a degree of specificity while
providing an environment that allows a variety of side-chains to
bind (Figure 1d, Fig. S2d).
Discussion
The structure presented here defines the interaction of the Cdc37
substrate with the PPP Ser/Thr phosphatase PP5. The conforma-
tion of the substrate is primarily dictated by interactions between
its backbone and residues of PP5 that line the active site. Inter-
actions between the side-chains of the Cdc37 substrate and PP5
are largely water-mediated and lie within spacious pockets that
form part of the Y-shaped channel that surrounds the catalytic
site. This channel is highly conserved in sequence and structure
throughout the PPP superfamily and, together, the use of the
main-chain of the substrate and the versatility provided by water-
mediated interactions to accommodate a range of side-chains
reveal how different members of this superfamily can accommo-
date a multitude of unrelated substrates with highly divergent
sequences. In addition these two factors suggest that the substrate
conformation observed here may provide a template for many
substrates that occupy the hydrophobic and C-terminal grooves
of the PPP superfamily.
Our structure illustrates the fundamental difference in the
mechanism of substrate binding at the catalytic sites of kinases
and phosphatases and shows how this is achieved on an atomic
level. For kinases the sequence of the substrate is critical in ensur-
ing specificity through highly conserved interactions dictated by
the substrate side-chains (26, 27), while Ser/Thr phosphoprotein
phosphatases allow sequence plasticity by providing an environ-
ment in which a variety of side-chains can be accommodated
within a conserved substrate backbone conformation.
While this sequence plasticity is a key feature of PPP substrate
recognition our biochemical and cell biology data indicate that,
contrary to the current widespread assumption in the field, the
catalytic subunit can confer some degree of local specificity.
Nonetheless regulatory subunits are still fundamental in control-
ling the primary specificity of a Ser/Thr PPP through their role
in recruiting substrates and increasing their local concentration;
thus phosphatases other than PP5 cannot dephosphorylate Cdc37
because they are unable to form the complete tripartite interac-
tion required for efficient dephosphorylation (8).
Our results delineate mechanistic details of one step in the
Hsp90-dependent kinase activation cycle for Cdk4 and Raf-1.
While the requirement for PP5-mediated dephosphorylation of
Cdc37 was previously known to be essential for activation of
several Hsp90 client kinases (8), its role at a molecular level
was not understood. The results presented here identify this
dephosphorylation step as a requirement for release of these
clients from the Hsp90 chaperone. Previous results suggest that
association of PP5 with Hsp90 chaperone complexes is accompa-
nied by structural changes since, within a purified Hsp90-Cdc37-
Cdk4 complex, the phospho-Ser13 Cdc37 substrate is inaccessible
to dephosphorylation by the non-specific lambda phosphatase
but readily accessible to dephosphorylation by PP5 (8). This is
further supported by recent results indicating that residues in the
vicinity of the Ser13 are responsible for binding client kinases (9,
22, 23) where it is likely to be buried. A conformational change
would therefore be required to allow PP5 access to its substrate. It
may be these conformational changes, rather than the absence of
the phosphorylation itself, that are the trigger for client release,
as eventual dephosphorylation by lambda phosphatase, which
occurs after prolonged incubation with the complex, does not
cause release of the Cdk4 client from the Hsp90-Cdc37 complex
(8).
While phosphorylation of Cdc37 Ser13 is essential for client
kinase activation in vivo (11, 12) and in vitro (28) its mechanis-
tic role remains enigmatic. In the cell the interaction of client
kinase with Cdc37 and its subsequent recruitment to Hsp90 is
likely to always occur with the phospho-Ser13 Cdc37, as CK2
is constitutively active. Phospho-Ser13 Cdc37 has a more stable
and compact conformation than wild-type (29), in which the
phospho-Ser13 is accessible to dephosphorylation by both calf
intestine alkaline phosphatase (29) and lambda phosphatase (8).
However, at least for the kinase B-Raf, this conformation is not a
requirement for either client versus non-client recognition (9) or
subsequent association with Hsp90 as a stable complex between
Hsp90, Cdc37 B-Raf can be formed from the individual proteins
in vitro in the absence of phosphorylation (22, 23) although
phospho-Ser13 enhances its stability (22). This is consistent with
recent data indicating that the primary interaction of Cdc37 with
B-Raf is via a distinct C-terminal domain of Cdc37 and is remote
from this site of phosphorylation (9, 23). Nonetheless our results
augment the set of known, non-overlapping residues, residing in
a relatively short stretch of the Cdc37 polypeptide that encom-
passes Ser13, responsible for interactions that regulate Cdc37
chaperone function, namely CK2 phosphorylation (11, 12), client-
kinase recognition in vitro (9), client-kinase complex formation in
vivo (20), and PP5 dephosphorylation.
PP5-mediated dephosphorylation of Cdc37 is one of a num-
ber of modifications that control progression of the chaperone
cycle, either by affecting cochaperone or client association. Phos-
phorylation of Y197 on Hsp90 dissociates Cdc37 from Hsp90
immune complexes, while phosphorylation of Y313 stimulates
association with Aha1 (21), the cochaperone required for the
enhancement of Hsp90’s ATPase activity and completion of one
round of the chaperone cycle (30). Indeed these two cochaper-
ones are not found in the same immune complexes (21), high-
lighting the degree of control imposed by these post-translational
modifications (PTMs).
We have identified the trapping of GR, a Cdc37-independent
Hsp90 client, on the Hsp90 chaperone when PP5 activity is abro-











































































































































cycle regulation beyond kinases alone. Serine/threonine phospho-
rylation of Hsp90 itself is, in general, found to result in reduced
affinity with clients (31-33). Client kinase release is also triggered
by tyrosine phosphorylation of Cdc37 on Y298 by the Src family
kinase, YES, and tyrosine phosphorylation of Hsp90 on Y627
dissociates Cdk4 (21). The latter modification also dissociates
Aha1 and PP5 fromHsp90 (21), and as such may be a mechanism
for terminating one cycle of chaperone activity. Together these
events emphasize the intricacy of the client activation process
and the many layers of control provided by serine/threonine and
tyrosine phosphorylation and its reversal.
Finally, this study demonstrates that both hyper- and hy-
poactivity of PP5 mutants enhances Hsp90 binding to its in-
hibitor ganetespib. Previous works have shown that PTM of co-
chaperones influence their activity. It remains to be seen whether
PP5 activity is also regulated by PTMs. Targeting the potential
enzymes that catalyze those PTMs may influence cell sensitivity
to Hsp90 inhibitors.
Methods
See SI Materials and Methods for details. Brieﬂy, the chimera protein,
comprising the catalytic domain of PP5 (residues 175-499) and a peptide
comprising residues 5-20 of Cdc37, with the mutation S13E, joined by a 9-
residue ﬂexible linker was generated by PCR. The protein was puriﬁed to
homogeneity using standard chromatographic techniques, and crystallised
using hanging drop vapour diffusion. Data were processed using XDS (34) &
Scala (35). The structure was solved by molecular replacement of PDB 1S95
using Phaser (36), and reﬁned using Phenix Reﬁne (37) with manual rebuild-
ing in Coot (38). Data collection and reﬁnement statistics are summarized in
Table S1. In vitro dephosphorylation was assessed using anti-phosphoSerine
13 antibody (Sigma). Immunoprecipitation assays in transiently transfected
HEK293 cells were carried out using anti-FLAG (Sigma) or anti-myc (Ther-
moScientiﬁc) antibody conjugated beads. Biotinylated ganetespib (Synta
Pharmaceuticals) and streptavidin agarose (ThermoScientiﬁc) were used for
drug binding assays. siRNA knock-down of PP5 (Origene) was carried out
using standard methods.
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